Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest announcement is out from Imugene ( (AU:IMU) ).
Imugene Limited has notified the market of the issue of a small tranche of unquoted options, with 4,544 IMUAJ options expiring on 30 June 2028 and exercisable at $0.86 being issued on 26 and 30 March 2026. These options form part of previously announced, unquoted equity transactions and are not intended to be quoted on the ASX, signaling a routine capital management step with limited immediate impact on its trading securities.
The issuance underscores Imugene’s continued use of unquoted equity instruments as part of its broader financing and incentive structures, rather than a major new capital raise. For shareholders and stakeholders, the move represents incremental potential future dilution but aligns with standard practice for ASX-listed biotechs seeking to balance funding flexibility with controlled market issuance.
The most recent analyst rating on (AU:IMU) stock is a Hold with a A$0.13 price target. To see the full list of analyst forecasts on Imugene stock, see the AU:IMU Stock Forecast page.
More about Imugene
Imugene Limited is an Australia-based biotechnology company listed on the ASX under the code IMU. The company operates in the life sciences sector, focusing on developing innovative therapies, with its capital management activities including the issuance of various equity securities and options to support corporate and development objectives.
Average Trading Volume: 1,676,388
Technical Sentiment Signal: Strong Sell
Current Market Cap: A$48.2M
Find detailed analytics on IMU stock on TipRanks’ Stock Analysis page.